BGB-8035

SKU: orb1744213

Description

BGB-8035 is a potent, selective, and orally bioavailable small molecule inhibitor targeting BTK, with additional activity against TEC and EGFR kinases. It is utilized in preclinical research for oncology and autoimmune diseases, demonstrating antitumor efficacy in both cellular assays and animal models.

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 2283349-24-4
• MW: 453.53
• Purity: 96.74%
• Formula: C₂₄H₃₁N₅O₄
• SMILES: C(N)(=O)C1=C2N([C@@H](CCN2)C3CCN(C(C=C)=O)CC3)N=C1C4=CC(OC)=C(C)C(OC)=C4
• Target: EGFR,BTK

Bioactivity

• Target IC50:
  BTK:1.1 nM|TEC:99 nM|EGFR:621 nM
• In Vivo:
  In 9-week-old female NOD/SCID mice harboring REC-1 MCL xenografts, BGB-8035 (administered at doses of 7.5, 15, and 30 mg/kg; oral dosing; twice daily) exhibited dose-dependent antitumor activity, with corresponding Tumor Growth Inhibition (TGI) values of 64.1%, 73.6%, and 79.9%, respectively.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

BGB 8035, BGB8035, BTK, TEC

Compound Identifiers

PubChem CID

146623164